[["index.html", " 《nanaoku》", " 《nanaoku》 "],["rawdoc.html", "1 rawdoc", " 1 rawdoc "],["catype.html", "2 catype", " 2 catype "],["mnotes.html", "3 mnotes 3.1 700072580 3.2 700150240 3.3 700180657 3.4 700350999 3.5 700385854 3.6 701057711 3.7 701265877 3.8 701284346", " 3 mnotes 3.1 700072580 3.1.1 210512 {post IPP meeting following up} the schedule with regimen for PBSCT for the patient is disclosed in the meeting. the estimated total amount of busulfan used in the time table is 15 vials. based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight 85kg 5 vials per day for 3 days (2021-05-12, 2021-05-13, 2021-05-14) pharmacy staff in charge of drug purchasing will get the inventory ready before the coming prescribing. people for dispensing regimen during weekend are also arranged. preparation and administration precautions: busulfan: do not use polycarbonate syringes or polycarbonate filter needles with the drug. etoposide: precipitation may be exacerbated at concentrations of 0.4 mg/mL or above. etoposide 400mg/m2 x body surface area 2m2 -&gt; amount 800mg. total solution containing 800mg etoposide will be no less than 2000mL. 3.2 700150240 3.2.1 210510 {problem list} the active problems listed in the TPR sheet are shown as following: - pneumonia - UTI - hypertension - ileus - hyponatremia [objective] urine OB 1+ (2021-05-08) urine bacteria 1+ (2021-05-08) CRP 5.39 (2021-05-08) D-dimer 1763ng/mL (2021-05-08) hs-Troponin I 49pg/mL (2021-05-08) Na 121mmol/L (2021-05-08) BUN 57mg/dL (2021-05-08) Creatinine 1.71mg/dL (2021-05-08) WBC 15.55 (2021-05-08) RBC 2.68 (2021-05-08) MCV 97.4 (2021-05-08) serum glucose 177mg/dL (2021-05-08) no defecation recorded in these 2 days [assessment] vital signs, including blood pressure, looks relatively stable. if no other special consideration exists, the first priority should be controlling the infections. brosym 2000mg IVD Q12H has been prescribed to control the infection since 2021-05-09. the lower serum sodium might be improved by intaking salted food. lab data showed a higher serum glucose level, an one-point datum might not lead to its trend, more data to form a time series of blood sugar monitoring is recommended. MCV almost touched the upper limit of the normal range, some folic acid and/or vit B12 supplements might be helpful for the mild anemia. some laxative agent might be helpful for the ileus. [suggestion] keep abx using and monitoring changes of infection signs. invite dietitian to help the patient to eat more salted diets and to see if any other diet issue found, then get sodium tested few days later. order regular scheduled blood sugar tests to build its trend. folacin (folic acid 5mg) and/or kentamin (thiamine 50mg, pyridoxine 50mg, cyannocobalamin 500mcg) are available in pharmacy inventory now, each of them could be administrated QD or BID, which is recommended. if still no defecation before 2021-05-11, then dulcolax (bisacodyl 5mg) QD or BID could be considered to prescribe, and administrated until defecation or 3 days then reevaluate the condition. 3.3 700180657 3.3.1 999999 {colon cancer} 2018-02 diagnosed with adenocarcinoma of S-colon, cT3N0M0. 2018-02-13 patho: pT3N0M0(0/16), G2, LV(-), Perineral(-), stage IIA. 2018-12-25 CT: soft tissue mass with necrotic margin at surface of uterus up to 2.9cm in largest dimension which is new in comparison to CT dated on 2018-06-02. 2019-01-03 PET a glucose hypermetabolic lesion on the superior aspect of the uterus. should be malignancy with pelvic seeding on the uterus. increased FDG accumulation in the right lateral aspect of the abdomen and pelvic region and in the anterior aspect of the pelvic region. 2019-01-04 sigmoidfiberscopy: an ulcerative tumor, about 1/3 circumferential bowel lumen at 18cm above AV (RS-colon) with easy contact bleeding previous anastomosis (10cm AAV) looked well. 2019-01-10 low anterior resection (LAR) and hysterectomy plus bilateral salpingo-oophorectomy (BSO) recurrent 3cm tumor (favor seeding) involving uterus and upper rectum and a segment of small bowel was identified. IHC stain: CK20(+), CK7(focal+), vimentine(-) patho: rT4bN0M1a, stage IVA. 2019-09-20 received 12th Avastin &amp; 14th FOLFOX6, mild fingers and feet numbness, pigmentation on breast skin. 2019-10-15 refilled Xeloda (capecitabine), mild fatigue, nausea, abdomen discomfort. 2019-11-26 refilled Xeloda (capecitabine), nail and finger pigmentation, mild fatigue and numbness. 2020-03-25 CT: a known newly-developed soft tissue nodule measuring 0.6 cm in right pelvic wall is noted again, increasing in size. 2020-04-07 PET a glucose hypermetabolic lesion in the right anterior pelvic wall, compatible with a metastatic lesion. multiple glucose hypermetabolic lesions in the left lower abdomen and in the pelvic cavity and a glucose hypermetabolic lesion in the left upper abdomen. 2021-02-20 CT: progression of peritoneal tumors with left lower ureter invasion causing left hydronephrosis and hydroureter. regimen 2018-03-03 ~ …. ~ …: Ufur (tegafur + uracil) …. ~ … ~ 2020-07-03: FOLFOX + Avastin (bevacizumab) 2020-07-17 ~ 2021-02-19: FOLFIRI + Cyramza (ramucirumab) 2021-03-31 ~ up to now : Opdivo (nivolumab) CEA 2021-04-28 8.64 2021-03-29 15.23 2021-03-02 16.89 2021-01-23 13.56 2020-10-28 5.044 2020-06-22 12.062 2020-03-18 8.714 2019-12-09 2.008 2019-08-16 0.866 2019-04-30 1.534 2018-12-10 15.635 2018-09-10 2.047 3.4 700350999 3.4.1 210510 {problem list} active problems listed in 2021-05-08 14:14 DutyNote containing 2 items: - urinary tract infection - right lower lung pneumonia [subj/obj] admitted on 2021-05-08 for lethargy, weakness for 5 days and fever for 1 day. with underlying HFrEF, bladder cancer s/p TURBT, HCVD, CKD and DM, been regularly followed up at our cardiology, urology, metabolism departments. bladder cancer causing voiding difficulties and UTI K 3.1mmol/L (2021-05-10), 3.1mmol/L (2021-05-08) BUN 123mg/dL (2021-05-10), 101mg/dL (2021-05-08) Creatinine 4mg/dL (2021-05-10), 3mg/dL (2021-05-08) eGFR 15 (2021-05-10), 20 (2021-05-08) CRP 8.63 (2021-05-10), 5.31 (2021-05-08) RBC 4x10^6/uL (2021-05-10), 3.7x10^6/mL (2021-05-08) HGB 11.6g/dL (2021-05-10), 10.8 (2021-05-08) MCV 84.8 fL (2021-05-10), 86.2 fL (2021-05-08) urine OB 2+, sediment-RBC 6-9, sediment-WBC &gt;= 100, Bacteria 3+ (2021-05-08) hs-Troponin I 385pg/mL (2021-05-08) serum glucose 177mg/dL (2021-05-08), records fluctuate between 126-226 from 2021-05-08 19:00 to 2021-05-10 11:30. HbA1c 8.1 (2021-04-27), 8.6 (2021-03-01), 10.1 (2020-12-11), 9.6 (2020-09-17), 9.8 (2020-06-24) Uric Acid 4.6mg/dL (2021-03-01), 6.1 (2021-01-19), 8.1 (2020-12-11), 9.3 (2020-09-17), 8.6 (2020-06-24) [assessment] vital signs looks relatively stable: body temp no more than 37.5 degrees Celsius since 2021-05-08, the fever has subsided. most of time SBP ranges in around 120-130, DBP 60-80, 3-day data showed BP is under well management. if there is no other special consideration, the first priority should be controlling the infections. avelox (moxifloxacin) 400mg IVD QD has been administrated since 2021-05-09 and scheduled till 2021-05-15. the patient has poor renal function, but no dosage adjustment necessary for avelox administration. although fever has gone, the rising CRP might hint the infection is still ongoing. the lower serum potassium might caused by uretropic (furosemide). lab data showed that blood suger flucturates in short-term (serum glucose), however the management is getting better in mid-term (HbA1c). using humalog mix50 pen (insulin lispro 50%, insulin lispro protamine 50%) QDAC and QNAC now. MCV almost touched the lower limit of the normal range, some iron supplements might be helpful for boosting up the hemoglobin level. uric acid seems fell into normal range for months, xanthine oxidase inhibitor could be no more necessary. [suggestion] keep abx using and monitoring any change of infection signs. invite dietitian to help the patient to get more potassium-containing food, and/or consider to shift uretropic (furosemide) to potassium sparing spironolactone. foliromin (ferrous sodium citrate, 50mg) BID for 2-4 weeks to levelup hemoglobin is recommended, administrated in combination with vit C to help absorption can be considered. if there is no special consideration, discontinuation feburic (febuxostat) is recommended. 3.5 700385854 3.5.1 210507 {colon cancer} [subj/obj] diagnosed with sigmoid adenocarcinoma in 2020 Apr with liver, paraaortic LNs, and peritoneal carcinomatosis, cT3N2bM1c, stage IVc. received FOLFIRI 80% dose and 11 times panitumumab from May to Oct in 2020 at Taoyuan General Hospital of Ministry of Health and Welfare. patho colon biopsy on 2020-11-26 showed one huge tumor was noted at sigmoid colon (30cm from anal verge) and the lumen was near completely obstructed. colonic tissue with invasive irregular neoplastic glands. immunohistochemical stains reveal CDX2(+) EGFR(+), PMS2(+), MLH1(focal +), MSH2(+), and MSH6(+). received FOLFIRI 6 times from 2020 Nov to 2021 Mar (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15) in our hospital prior to this hospitalization. NRAS/KRAS reported on 2020-12-15 showing not detected. CEA 16.62ng/mL(2021-01-26), 8.52ng/mL(2020-11-17). BRAF lab data not found. [assessment] patients with tumors originating on the right side of the colon (hepatic flexure through cecum) are unlikely to respond to cetuximab and panitumumab in first-line therapy for metastatic disease. EGFR(+), KRAS/NRAS WT gene and left-sided tumor - panitumumab is purchased and will be ready for the patient in days. immune checkpoint inhibitors might not an ideal option for non-dMMR/MSI-H tumor - MLH1(focal +), MSH2(+), MSH6(+). according to CEA lab data, the condition might not be improved after one year FOLFIRI. [suggestion] might order CT scan to gather new evidence on treatment effect. If evidence shows that the cancer is getting more advanced, then shift FOLFIRI to FOLFOX or CAPEOX (each regimen can be used in combination with bevacizumab) could be considered. {substance dependence} [subj/obj] lab test showed evidence of using addictive drug. [assessment] should help the patient get rid of those illegal drugs. [suggestion] might arrange or refer the patient to an addiction treatment center or clinic to get some alternative e.g. methadone. {returning to society} [subj/obj] his family members avoid to contact him. no job, no income not standing on his own feet yet (financially) [assessment] being not reintegrated to the society will push him closer to the additive drugs. [suggestion] might arrange social work department staff to see if any help could be offered to him. 3.6 701057711 3.6.1 999999 D-colon cancer obstruction s/p self expandable metalic stent placed on 2020-07-16, and single-incision laparoscopic surgery (SILS) with left hemicolectomy on 2020-07-22109/7/22 patho colon segmental resection for tumor reported on 2020-07-28: tumor, descending colon, laparoscopic low anterior resection (LAR) - adenocarcinoma lymph node, mesocolic, dissection - Tumor metastasis (2/16) without extracapsular extension (0/2). AJCC pathologic staging pT4aN1b (if cM0), stage IIIB. histology grade G2: moderately differentiated with focal tumor necrosis, abscess and mucin production. ImmunoHistoChemistry for tumor cells: EGFR(+, 100%), PMS2(+), MLH1(+), MSH2(+) and MSH6(+). mFOLFOX6 adjuvant chemotherapy 12 cycles from 2020-08-14 to 2021-01-22. metastatic adenocarcinoma over left lower lung status post video-assisted thoracic surgery left lower lung wedge resection on 2021-02-26. shift chemo regimen to FOLFIRI since 2021-03-26. Decreased chemotherapy dose to 67 % for grade 3 diarrhea with blody weight loss. Decreased chemotherapy dose to 75 % for grade 2 diarrhea with blody weight loss. 3.7 701265877 3.7.1 999999 701265877 {Colon cancer} [subj/obj] (transverse) colon cancer with liver metastases, cT4aN1aM1c, stage IV s/p LPS right extended and hemicolectomy on 2020-03-26 and seedings over omentum found. patho peritoneum metastases, pT4aN2aM1c, stage IVc s/p radiofrequency ablation (RFA) with switch controller (SWC) x3 on 2020-08-25. patho result: poorly differentiated, EGFR (+), wildtype RAS, proficient MMR but B-Raf V600E mutation. chemo (palliative) from 2020-04-27 with FOLFOXIRI (ox: self-paid; iri: insurance covered) with bevacizumab. chest echography on 2021-02-23 showed right thorax pleural effusion s/p drainage of 600 cc. CXR on 2021-03-09 showed right thorax small pleural effusion. CEA: 1.85ng/mL(2021-05-04) 1.35ng/mL(2021-04-20) 1.18ng/mL(2021-04-06) 1.59ng/mL(2021-03-23) 1.90ng/mL(2021-03-09) CA199: 11764U/mL(2021-05-04) 4875U/mL(2021-04-20) 2068U/mL(2021-04-06) 1388U/mL(2021-03-23) 1557U/mL(2021-03-09) for 3 consecutive weeks then 1 week off as a cycle Oral target therapy with Cobimetinib 20mg 1# po QD (self-carried) (for 3 consecutive weeks then 1 week off as a cycle) from 2021/02/24~2021/0314. Oral target therapy with Dabrafenib 75mg 2# po Q12H (self-carried) (for 3 consecutive weeks then 1 week off as a cycle) from 2021/02/24. Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C1D1) on 2021/02/24, (C1D15) on 2021/03/10, (C2D1) on 2021/03/24, (C2D15) on 2021/04/07. Oral target therapy with Mekinisc 2mg 1# po QDAC(self-paid) from 2021/03/15 (for 3 consecutive weeks then 1 week off as a cycle). Therefore, the treatment would be cetuximab plus irinotecan(C1D15) and dabrafenib and MEK inhiitor, under the recognition of T-colon cancer with metastases to liver, peritoneum and pleura, and with B-Raf mutation. This time, she was admitted for Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C3D1) on 2021/4/22. Oral target therapy with Dabrafenib(Tafinlar) 75mg 1# po BID(self-carried) from 2021/02/24 Oral target therapy with Mekinisc 2mg 1# po QDAC(self pay) from 2021/03/15. Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C3D1) from on 2021/04/23 3.8 701284346 3.8.1 210512 {drug identification} requesting drug identification for 6 items. the 4 identified items has been shown as following while the other 2 items still remain unknown: - sinemet (carbidopa 25mg, levodopa 100mg) - urief (silodosin 4mg) - rivotril (clonazepam 2mg) - through (sennoside 12mg) these drugs will be sent back to ward by the in-hospital porter. "]]
